Hold Torrent Pharmaceuticals; target of Rs 3235: ICICI Direct
ICICI Direct recommended hold rating on Torrent Pharmaceuticals with a target price of Rs 3235 in its research report dated January 27, 2022.29-01-2022
29-01-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Shares28-01-2022
Torrent Pharma's Q3 brings pain to stock
The performance of Torrent Pharma's US business has been dismal with revenues down by 20% y-o-y.Better growth in other countries lifted total revenues, but weaker margins hit net profit27-01-2022
Torrent Pharma tumbles 14% on disappointing Q3 results
In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.27-01-2022
Earnings Call for Q3FY22 of Torrent Pharmaceuticals
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.26-01-2022
Torrent Pharma Q3 profit falls 16% to Rs 249 cr, declares Rs 25 interim dividend
The company's total revenue rose 6 per cent to Rs 2,108 crore during December quarter.25-01-2022
Q3FY22 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Pharmaceuticals company Torrent Pharmaceuticals declares Q3FY22 result: Revenue at Rs. 2,108 crores up by 6% Gross margins: 70%; EBITDA margins: 28%. EBITDA at Rs. 585 crores was down by 5%. Profit before tax at Rs. 357 crores was flat. Net profit after tax at Rs. 249 crores was down by 16%. Commenting on the Q3 results, Samir Mehta, Chairman, said “Due to the prolonged delays in reinspection of our US facilities on account of the pandemic, coupled with higher than anticipated pricing pressure, our US business has been adversely affected during this quarter. We remain hopeful of our prospects in the US market as soon as the facilities are reinspected. We have initiated cost optimisation measures which should help us get back on track with respect to margins in the upcoming quarters. Our India business continues to be on a strong footing delivering significantly higher than market growth during the quarter.” Result PDF25-01-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Dividend Updates
We would like to inform that the Board has at its meeting held today approved an interim dividend of Rs. 25/- (500 %) per equity share of Rs. 5/- fully paid up. The dividend is expected to be paid / dispatched on or around 11th February, 2022.25-01-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
The presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2021 to be made to analysts is enclosed for your records.25-01-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Submission / Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, (''Listing Regulations'')
We would like to inform that the Board has at its meeting held today approved, inter-alia, the following: 1) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and nine months ended on 31st December, 2021. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and nine months ended on 31st December, 2021. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com. A Press Release on Financial Results which is being submitted to the media is also enclosed herewith.25-01-2022